Anthropic launched "Claude for Life Sciences" on October 20, 2025, marking its first formal entry into the biotech and pharmaceutical sectors. This new offering leverages Anthropic's existing Claude AI models, but with crucial enhancements tailored for scientific research and development. The initiative aims to support the entire drug discovery process, from early-stage research to commercialization.
Key to Claude for Life Sciences are new integrations with widely used scientific platforms such as Benchling, PubMed, BioRender, Scholar Gateway (by Wiley), Synapse.org, and 10x Genomics. These connectors enable Claude to access and process vast amounts of scientific data, records, and literature. For instance, the Benchling connector allows Claude to respond to scientists' questions with links to source experiments and generate protocols and consent documents, while PubMed provides access to millions of biomedical articles. Anthropic also announced partnerships with expert AI adoption companies like Caylent, KPMG, Deloitte, and cloud providers AWS and Google Cloud to facilitate integration for life sciences organizations.
The new offering is designed to address time-consuming and expensive aspects of scientific workflows. Tasks that previously took days, such as comparing study designs or drafting reports for regulatory submissions, can now be completed in minutes, as demonstrated in a preclinical study comparison. Claude for Life Sciences assists with literature reviews, hypothesis generation, bioinformatics and data analysis (including genomic data), and drafting and reviewing regulatory submissions. The company's latest model, Claude Sonnet 4.5, shows significant improvements in life sciences tasks, scoring 0.83 on Protocol QA—a benchmark for understanding laboratory protocols—against a human baseline of 0.79.
Anthropic's head of biology and life sciences, Eric Kauderer-Abrams, emphasized the company's goal for a "meaningful percentage of all of the life science work in the world to run on Claude." While acknowledging that AI cannot magically shorten lengthy processes like multi-year clinical trials, the focus is on improving efficiency in each specific part of the discovery process where AI can make a difference. The company is committed to responsible AI development and aims to empower researchers to make new discoveries, with a future vision for AI models to achieve autonomous discoveries.
